Loading
Beta Bionics, Inc. Stock: price and insider trades · United States
US·Mcap US$910.1M
Beta Bionics, Inc.: what insiders have been doing
Beta Bionics, Inc. is a listed company. Filings by its managers are published through SEC (Form 4). The last twelve months, up to 18 October 2026, brought 82 filings signed by 18 insiders.
The flow runs one way only: 40 sales worth €3.6M, from 8 insiders, and no purchase. The totals do not cover 4 filings with an undisclosed amount. At €585k, the sale published on 10 September 2026 by Hopman Mark is the largest of the period (0.057% of market cap).
With 82 filings in twelve months, the company is more active than the median of 19 filings across the 5,814 companies we follow on the same exchange. Since 2025, the database holds no purchases and 54 sales by insiders of the company. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 100.3 m USD and net income of -73.2 m USD.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
In the same market, recent insider purchases at GameStop Corp. and Heico Corp also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
117
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€4M
54 ops. · all time
Who traded when
BuySaleMark Hopman14 sales
Stephen Feider11 sales
Mike Mensinger8 sales
Sean Saint6 sales
Steven Jon Russell5 sales
Christy Jones4 sales
+2 other insiders
Analyst consensus: bullish or bearish?
Analysts rate Beta Bionics, Inc. Buy (bullish), based on 14 analysts. Average price target: US$24.24.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,292 of 24,158 companies
24.1
score / 100
Value19
Quality29
FCF yld-6.4%
Earn yld-8.3%
EV/EBITDA·
ROE-26%
Gross mgn55%
Net mgn-73%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$16.87
Analyst consensus
14 analystsBuy
US$16.00Target US$24.24(+44%)US$30.40
Income statement
RevenueUS$100.3M
Gross profitUS$55.5M55% margin
EBITDA-US$68.8M-69% margin
Net income-US$73.2M-61.3% margin
Valuation
PER (forward)-7.8x
P/Book3.0x
Balance sheet & cash
Market capUS$910.1M
Total debtUS$7.3M
Free Cash Flow-US$56.2M
Debt / Equity3%
Profitability & ownership
ROE-26.2%
ROA-16.7%
% insiders0.8%
% institutions112.8%
Last declaration on 16 October 2026
Declarations117 total
775 shares@ US$17.35Common StockSEC:0002048497-26-000021:0
370 shares@ US$18.960.0007% mcap0.3% of flowCommon StockSEC:0002048497-26-000018:0
2,660 shares@ US$18.980.0048% mcap6.2% of flowCommonSEC144:0001950047-26-009970
6,430 shares@ US$23.000.013% mcap71.7% of flowCommon StockSEC:0002048467-26-000007:0
8,942 shares@ US$22.040.017% mcap85.1% of flowCommonSEC144:0001950047-26-009750
35,994 shares@ US$18.46280.055% mcap29.0% of flowCommon StockSEC:0002048497-26-000016:0
30,779 shares@ US$20.13190.052% mcap27.3% of flowCommon StockSEC:0002048497-26-000015:0
2,650 shares@ US$22.000.0049% mcap11.1% of flowCommon StockSEC:0002048500-26-000013:0
5,300 shares@ US$19.230.0086% mcap100.0% of flowCommonSEC144:0001950047-26-009580
28,119 shares@ US$19.230.045% mcap100.0% of flowCommonSEC144:0001950047-26-009571
775 shares@ US$15.520.0010% mcap0.5% of flowCommon StockSEC:0002048497-26-000014:0
36,870 shares@ US$18.46280.057% mcap29.7% of flowCommon StockSEC:0002048497-26-000013:0
40,305 shares@ US$19.330.065% mcap100.0% of flowCommonSEC144:0001950047-26-009247
5,641 shares@ US$20.07780.0095% mcap13.7% of flowCommon StockSEC:0002048593-26-000010:0
5,327 shares@ US$19.11310.0085% mcap4.5% of flowCommon StockSEC:0002048497-26-000012:0
4,375 shares@ US$19.11310.0070% mcap15.8% of flowCommon StockSEC:0002048500-26-000012:0
6,675 shares@ US$19.11310.011% mcap13.1% of flowCommon StockSEC:0002048588-26-000013:0
16,867 shares@ US$19.11310.027% mcap39.2% of flowCommon StockSEC:0002048593-26-000009:0
4,221 shares@ US$19.11310.0068% mcap43.0% of flowCommon StockSEC:0002051384-26-000009:0
5,641 shares@ US$20.07780.0095% mcap100.0% of flowCommonSEC144:0001628280-26-060356
5,327 shares@ US$19.4150.0087% mcap53.3% of flowCommon StockSEC144:0002048497-26-000011
4,375 shares@ US$19.4150.0071% mcap60.4% of flowCommon StockSEC144:0002048500-26-000011
6,675 shares@ US$19.4150.011% mcap33.4% of flowCommon StockSEC144:0002048588-26-000012
16,867 shares@ US$19.4150.027% mcap60.4% of flowCommon StockSEC144:0002048593-26-000008
4,221 shares@ US$19.4150.0069% mcap60.4% of flowCommon StockSEC144:0002051384-26-000008
25 of 117 declarations
About Beta Bionics, Inc.
Beta Bionics, Inc. is a company focused on developing medical technologies for diabetes treatment. It aims to create innovative devices to enhance disease management.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
